About IMIDomics
IMIDomics is a company based in San Francisco (United States) founded in 2015 by Sara Marsal. IMIDomics has raised $16.5 million across 4 funding rounds from investors including Evotec, UCB and European Union. IMIDomics offers products and services including IMID Drug Pipeline and IMID-Biobank. IMIDomics operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
- Headquarter San Francisco, United States
- Founders Sara Marsal
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Imidomics Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16.5 M (USD)
in 4 rounds
-
Latest Funding Round
Not available
-
Investors
Evotec
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of IMIDomics
IMIDomics offers a comprehensive portfolio of products and services, including IMID Drug Pipeline and IMID-Biobank.
Develops targeted medicines for immune-mediated inflammatory diseases using data.
Manages clinical and biomolecular data for drug discovery applications.
People of IMIDomics
Unlock access to complete
Unlock access to complete
Funding Insights of IMIDomics
IMIDomics has successfully raised a total of $16.5M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in IMIDomics
IMIDomics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Evotec, UCB and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US private equity investments are managed by DNS Capital.
|
Locked | Locked | Locked | |
|
Growth-equity investments are managed by the private investment firm.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for IMIDomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by IMIDomics
Investment portfolio details for IMIDomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - IMIDomics
Detailed financials for IMIDomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Imidomics Comparisons
Peer comparison for IMIDomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of IMIDomics
IMIDomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Therapies for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of IMIDomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Imidomics
Complete news archive for IMIDomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IMIDomics
IMIDomics was founded in 2015 and raised its 1st funding round 5 years after it was founded.
IMIDomics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Fred Craves is the current CEO of IMIDomics.
IMIDomics is a funded company, having raised a total of $16.5M across 4 funding rounds to date.
Founded in 2015 and based in San Francisco, United States, IMIDomics operates in the biotechnology sector. Exclusive data access is combined with biological insights to enable precision discovery of treatments for immune-mediated inflammatory diseases. Operations focus on targeting specific mechanisms in these conditions, with medicines developed to address unmet needs in inflammatory disorders.
IMIDomics's top competitors include ADMA Biologics, BioNTech and Generate Biomedicines.
IMIDomics offers IMID Drug Pipeline and IMID-Biobank.
IMIDomics has 7 investors. Key investors include Evotec, UCB, European Union, Bristol-Myers Squibb, and DNS Capital.